Marimed SEC Filings

MariMed Inc. (MRMD) reported Q3 2025 results. Revenue was $40,764,000 with gross profit of $16,363,000. The quarter showed a net loss of $2,941,000 as interest expense and a $2,759,000 tax provision offset operating income of $1,599,000. Adjusted EBITDA was $5,139,000.

Year to date, revenue totaled $118,176,000 with a net loss of $9,815,000. Cash and equivalents were $6,596,000, and net cash provided by operating activities was $4,266,000. Mortgages and notes payable totaled $73,186,000, including $56,324,000 under the CREM loan. Shares outstanding were 394,452,517 as of September 30, 2025; 395,073,625 were outstanding as of November 3, 2025.

The First State Compassion Center acquisition closed March 1, 2025 and contributed $3,900,000 of revenue and $2,400,000 of net income in Q3. In the quarter, 1,155,274 Series C preferred shares converted into 5,776,370 common shares. The company later announced an exit from Missouri operations effective October 28, 2025.

MariMed Inc. furnished a Form 8-K stating it issued a press release with financial results for the three- and nine-month periods ended September 30, 2025.

The press release is included as Exhibit 99.1 and, under Item 2.02 and General Instruction B.2, is furnished and not deemed filed under the Exchange Act.

MariMed (MRMD) insider update: Chief Operating Officer Timothy Shaw reported routine equity transactions on 10/27/2025. He converted 111,112 restricted stock units into common stock (Code M; price $0), then had 32,612 shares withheld to cover taxes (Code F) at $0.1579 per share. Following these transactions, Shaw beneficially owns 9,133,912 shares directly. He also has 2,000,000 shares held indirectly by the Shaw Family Trust. The RSUs were granted on October 27, 2022 and are now fully vested, with no unvested RSUs remaining under that grant.

MariMed (MRMD) reported an insider equity change by President and CEO Jon R. Levine. On 10/27/2025, 138,888 restricted stock units converted one-for-one into common shares. To cover taxes on the vesting, the issuer withheld 40,764 shares at a price of $0.1579 under a tax-withholding transaction.

After these transactions, Levine held 20,953,494 shares directly. In addition, 6,684,640 shares are held indirectly by the Jon Levine Family Trust for the benefit of his spouse and children; Levine disclaims beneficial ownership of those securities. The RSUs were originally granted on October 27, 2022, and there are no unvested RSUs remaining under that grant.

Marimed Inc. Chief Operating Officer Timothy Shaw reported transactions on 10/02/2025 showing receipt of 9,981 restricted stock units (RSUs) that convert one-for-one into common shares and the vesting-triggered withholding of 2,930 shares to satisfy taxes at $0.161 per share. After these transactions Mr. Shaw directly beneficially owns 9,055,412 shares and indirectly holds 2,000,000 shares through the irrevocable Shaw Family Trust, for a combined reported interest disclosed on the Form 4.

Jon R. Levine, who is listed as President and CEO, Director, and a 10% owner of Marimed Inc. (MRMD), reported transactions on 10/02/2025. 11,517 restricted stock units (RSUs) vested and were converted one-for-one into common shares; the filing shows an acquisition of 11,517 shares at a $0 price component and a separate disposition of 3,381 shares withheld by the issuer to satisfy tax-withholding obligations at a price of $0.161 per share. After these reported transactions, the filing lists 20,855,370 shares beneficially owned directly and 6,684,640 shares held indirectly by the Jon Levine Family Trust for the benefit of his spouse and children (the reporting person disclaims beneficial ownership of the trust shares). The RSU grant referenced was originally awarded on April 2, 2024 and remaining installments vest in three equal parts on April 2, 2026, October 2, 2026, and April 2, 2027.

Mario Pinho, Chief Financial Officer of MARIMED INC. (MRMD), reported transactions dated 09/30/2025 related to restricted stock units (RSUs) granted earlier in 2025. On that date 53,572 RSUs were reported as acquired (Code M) and converted one-for-one into common stock, resulting in 53,571 shares beneficially owned from those RSUs. The issuer withheld 15,347 shares to satisfy tax withholding, recorded as a disposition at a price of $0.1635 per share, leaving the reporting person with 195,611 shares beneficially owned after the transactions. The RSUs were originally granted on February 17, 2025 and the remaining RSUs will vest on December 31, 2025 per the award agreement.

Ryan Crandall, Chief Commercial Officer of Marimed Inc. (MRMD), reported Section 16 transactions on 09/28/2025. 6,046 restricted stock units (RSUs) vested and were converted one-for-one into common shares. The issuer withheld 1,775 shares to satisfy tax-withholding obligations at a reported price of $0.143 per share. After these transactions the reporting person beneficially owned 731,938 shares. The vested RSUs were originally granted on 09/28/2024 and the remaining RSUs will vest in three equal installments on 03/28/2026, 09/28/2026 and 03/28/2027.

Timothy Shaw, Chief Operating Officer and director of Marimed Inc. (MRMD), reported vesting and related transactions on 09/15/2025. 81,772 restricted stock units (RSUs) converted into 81,772 shares and were reported as acquired at $0 per share; the RSUs were granted on May 23, 2025 and the remaining portion will vest on December 15, 2025. To satisfy tax withholding on the vesting, 24,001 shares were withheld by the issuer at an effective price of $0.1374 per share. Following these transactions, the filing shows 9,048,361 shares beneficially owned directly and 2,000,000 shares held indirectly by the Shaw Family Trust (for the benefit of the reporting person’s children), of which Mr. Shaw disclaims beneficial ownership.